Current Problems in Cancer最新文献

{"title":"Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies","authors":"Nadine Mallak ,&nbsp;Burcak Yilmaz ,&nbsp;Catherine Meyer ,&nbsp;Celeste Winters ,&nbsp;Anna Mench ,&nbsp;Abhinav K. Jha ,&nbsp;Vikas Prasad ,&nbsp;Erik Mittra","doi":"10.1016/j.currproblcancer.2024.101129","DOIUrl":"10.1016/j.currproblcancer.2024.101129","url":null,"abstract":"<div><p>Advancements in somatostatin receptor (SSTR) targeted imaging and treatment of well-differentiated neuroendocrine tumors (NETs) have revolutionized the management of these tumors. This comprehensive review delves into the current practice, discussing the use of the various FDA-approved SSTR-agonist PET tracers and the predictive imaging biomarkers, and elaborating on Lu177-DOTATATE peptide receptor radionuclide therapy (PRRT) including the evolving areas of post-therapy imaging practices, PRRT retreatment, and the potential role of dosimetry in optimizing patient treatments. The future directions sections highlight ongoing research on investigational PET imaging radiotracers, future prospects in alpha particle therapy, and combination therapy strategies.</p></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"52 ","pages":"Article 101129"},"PeriodicalIF":2.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142129137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Information for Readers","authors":"","doi":"10.1016/S0147-0272(24)00078-3","DOIUrl":"10.1016/S0147-0272(24)00078-3","url":null,"abstract":"","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"52 ","pages":"Article 101137"},"PeriodicalIF":2.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0147027224000783/pdfft?md5=9db5d3189d1105a34bd305df63288304&pid=1-s2.0-S0147027224000783-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142241200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Title Page","authors":"","doi":"10.1016/S0147-0272(24)00077-1","DOIUrl":"10.1016/S0147-0272(24)00077-1","url":null,"abstract":"","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"52 ","pages":"Article 101136"},"PeriodicalIF":2.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0147027224000771/pdfft?md5=5969f9b33c1231049b7377fc96f63121&pid=1-s2.0-S0147027224000771-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142241199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastroenteropancreatic neuroendocrine tumors: Epigenetic landscape and clinical implications","authors":"Hannah S. McMurry ,&nbsp;Jaydira Del Rivero ,&nbsp;Emerson Y. Chen ,&nbsp;Adel Kardosh ,&nbsp;Charles D. Lopez ,&nbsp;Guillaume J. Pegna","doi":"10.1016/j.currproblcancer.2024.101131","DOIUrl":"10.1016/j.currproblcancer.2024.101131","url":null,"abstract":"<div><p>Neuroendocrine tumors (NETs) are a rare, heterogenous group of neoplasms arising from cells of the neuroendocrine system. Amongst solid tumor malignancies, NETs are notable for overall genetic stability and recent data supports the notion that epigenetic changes may drive NET pathogenesis. In this review, major epigenetic mechanisms of NET pathogenesis are reviewed, including changes in DNA methylation, histone modification, chromatin remodeling, and microRNA. Prognostic implications of the above are discussed, as well as the expanding diagnostic utility of epigenetic markers in NETs. Lastly, preclinical and clinical evaluations of epigenetically targeted therapies in NETs and are reviewed, with a focus on future directions in therapeutic advancement.</p></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"52 ","pages":"Article 101131"},"PeriodicalIF":2.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical treatment of neuroendocrine tumors","authors":"Kristin Trone,&nbsp;Rodney Pommier","doi":"10.1016/j.currproblcancer.2024.101132","DOIUrl":"10.1016/j.currproblcancer.2024.101132","url":null,"abstract":"","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"52 ","pages":"Article 101132"},"PeriodicalIF":2.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142048308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of carcinoid heart disease","authors":"Madelaine Hack ,&nbsp;Castigliano M Bhamidipati","doi":"10.1016/j.currproblcancer.2024.101128","DOIUrl":"10.1016/j.currproblcancer.2024.101128","url":null,"abstract":"<div><p>Carcinoid Heart Disease (CaHD) is defined as the constellation of all cardiac manifestations that occur in patients with carcinoid tumors. Cardiac manifestations are generally due to the paraneoplastic effects of vasoactive substances secreted by carcinoid tumors. These primarily cause cardiac valve dysfunction and resultant heart failure. Successful management of patients with CaHD requires a multidisciplinary team to address both the classical manifestations of carcinoid syndrome, as well as the additional manifestations of cardiac dysfunction. While the cornerstone of medical management for carcinoid syndrome are somatostatin analogs (SSAs), there is no evidence to suggest that the usage of SSAs influences the development or progression of CaHD. Additionally, while liver-directed therapies provide a survival benefit to symptomatic carcinoid syndrome patients with resectable disease, there are conflicting data on the survival benefit of hepatic resection among patients with CaHD. Cardiac surgery in patients with CaHD is a complex undertaking, and is the only definitive treatment for symptom management in CaHD with significant survival benefit for patients in advanced disease states. Two crucial surgical decisions to be made are determining which valve(s) should be replaced, and what prosthetic should be utilized. While challenging in this often medically frail population, cardiac surgery confers a survival benefit and should be pursued in cases of symptomatic CaHD or progressive right ventricular dysfunction.</p></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"52 ","pages":"Article 101128"},"PeriodicalIF":2.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of functional neuroendocrine tumors","authors":"Amr Wahba ,&nbsp;Zi Tan ,&nbsp;Joseph S. Dillon","doi":"10.1016/j.currproblcancer.2024.101130","DOIUrl":"10.1016/j.currproblcancer.2024.101130","url":null,"abstract":"<div><p>Functional neuroendocrine neoplasms (NENs) are those associated with specific symptoms related to the hormonal secretion of the NENs. Although less than 25 % of NENs are functional at diagnosis,<span><span>¹</span></span> the associated syndromes significantly increase the patient burden of disease. Management of hormonal NEN symptoms may involve tumor resection or other reduction strategies (e.g., chemotherapy, embolotherapy, etc), but also specific therapies directed at decreasing hormonal synthesis, secretion, or end-organ effects. In this review, we focus on specific symptomatic management of many of the NEN syndromes, which may be pursued in addition to management primarily directed at tumor bulk and growth. A continued focus on symptom management related to the hormonal secretions of NENs, in the context of other efforts to reduce tumor bulk and growth, could significantly improve patient wellbeing.</p></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"52 ","pages":"Article 101130"},"PeriodicalIF":2.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142096368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Capivasertib in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative advanced breast cancer","authors":"Zaheer Qureshi ,&nbsp;Faryal Altaf ,&nbsp;Mikail Khanzada ,&nbsp;Zaofashan Zaheer ,&nbsp;Eeshal Fatima ,&nbsp;Muhammad Bakhtiar","doi":"10.1016/j.currproblcancer.2024.101114","DOIUrl":"10.1016/j.currproblcancer.2024.101114","url":null,"abstract":"<div><h3>Purpose</h3><p>This review discusses the role and efficacy of Capivasertib in managing Hormone Receptor-Positive (HR+) breast cancer.</p></div><div><h3>Summary</h3><p>Breast cancer is the most prevalent type of cancer among women worldwide. This article is an in-depth analysis of advanced therapeutic options involving Capivasertib in treating HR+ Breast Cancer. It focuses on the mode of action, efficacy, clinical trials, and comparison with fulvestrant alone. This review also highlights the therapy's precision in targeting specific cancer cells. Its mechanism of action involves preventing cancer cells from growing and having a cytotoxic effect on them. It improves progression-free survival while maintaining the quality of life. The side effects can be easily managed by dose reduction or discontinuation of the drug. This article sheds light on the ongoing trials and FDA recognition.</p></div><div><h3>Conclusion</h3><p>In conclusion, Capivasertib-fulvestrant therapy shows potential as an innovative therapeutic option for HR+ breast cancer but warrants additional research, especially in randomized control trials (RCT). It resulted in longer progression-free survival compared to fulvestrant alone. Its side effect profile is minimal.</p></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"51 ","pages":"Article 101114"},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of metastatic pheochromocytomas and paragangliomas: when and what","authors":"Vineeth Sukrithan ,&nbsp;Kimberly Perez ,&nbsp;Neeta Pandit-Taskar ,&nbsp;Camilo Jimenez","doi":"10.1016/j.currproblcancer.2024.101116","DOIUrl":"10.1016/j.currproblcancer.2024.101116","url":null,"abstract":"<div><p>Recently, the treatment landscape for metastatic pheochromocytomas and paragangliomas (MPPGL) has seen both progress and setbacks. We provide an up-to-date review of the multimodality management of MPPGL and discuss novel opportunities and current challenges in the treatment landscape. Given the unique clinical presentation of MPPGL, we discuss the management of hormone-related clinical sequelae and traditional modalities of therapy. Advances in the understanding of the molecular biology of these diverse tumors have enabled novel strategies such as augmenting DNA damage by targeted delivery of radionuclides such as ¹³¹I and ¹⁷⁷Lu, abrogating tumor angiogenesis, hypoxia resistance, and DNA damage repair. Despite progress, we address the significant challenges still faced by patients and researchers engaged in efforts to improve outcomes in these rare cancers.</p></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"51 ","pages":"Article 101116"},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0147027224000576/pdfft?md5=cc5b1245bfeaadc2862177d2b43c4d5d&pid=1-s2.0-S0147027224000576-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141638532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic risk stratification using C-reactive protein, albumin, and associated inflammatory biomarkers in patients with advanced cancer in palliative care","authors":"Geisiane Alves da Silva ,&nbsp;Livia Costa de Oliveira ,&nbsp;Emanuelly Varea Maria Wiegert ,&nbsp;Larissa Calixto-Lima ,&nbsp;Gabriella da Costa Cunha ,&nbsp;Wilza Arantes Ferreira Peres","doi":"10.1016/j.currproblcancer.2024.101115","DOIUrl":"10.1016/j.currproblcancer.2024.101115","url":null,"abstract":"<div><h3>Purpose</h3><p>To evaluate the prognostic value of C-reactive protein (CRP), albumin, CRP/albumin ratio (CAR), and modified Glasgow Prognostic Score (mGPS) at different thresholds in patients with advanced cancer in palliative care.</p></div><div><h3>Methods</h3><p>Prospective cohort study with patients evaluated at a palliative care unit in Brazil between July 2016 and March 2020. We included patients ≥ 20 years old, both sexes, able to provide the necessary information or accompanied by someone able to do so, and Karnofsky Performance Status ≥ 30 %. The exclusion criteria were the absence of laboratory data and previous diagnosis of autoimmune and infectious diseases. The thresholds analyzed were: CRP &lt; 5 vs. 5-10 vs. &gt; 10 mg/L, albumin &lt; 2.4 vs. 2.4-2.9 vs. 3.0-3.5 vs. &gt; 3.5 g/dL; CAR &lt;1.2 vs. 1.2–2.0 vs. &gt; 2.0, and mGPS equal to 0 vs. 1 vs. 2. Kaplan-Meier curves and Cox regression models (with hazard ratios [HR] and 95% confidence interval [CI]) were used to evaluate prognostic value, and the concordance statistic (C-statistic) was used to evaluate the predictive accuracy of these thresholds to predict death within 90 days.</p></div><div><h3>Results</h3><p>A total of 1,877 patients were included. Median overall survival was 51 (19;124) days and decreased in line with the deterioration of the inflammatory biomarkers. According to the Cox regression models, HR increased as the thresholds worsened (CRP: 1.74 [95% CI, 1.50-2.02] to 2.30 [95% CI, 2.00-2.64]; albumin: 1.77 [95% CI, 1.52-2.07] to 2.60 [95% CI, 2.15-3.14]; CAR: 1.47 [95% CI, 1.21-1.77] to 2.35 [95% CI, 2.05-2.69]; mGPS: 1.78 [95% CI, 1.40-2.23] to 1.89 [95% CI, 1.65-2.15]). All the inflammatory biomarkers evaluated showed discriminatory accuracy for predicting death (C-statistic &gt;0.70), with CAR as the best parameter (C-statistic: 0.80).</p></div><div><h3>Conclusion</h3><p>Our results suggest that CRP, albumin, CAR, and mGPS can be used as clinically meaningful biomarkers to stratify patients with advanced cancer in palliative care according to the severity of these indicators.</p></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"51 ","pages":"Article 101115"},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141472820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}